English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/152544
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

AuthorsBenchekroun, M.; Romero, A. ; Egea, Javier; León, Rafael; Michalska, P.; Buendía, I.; Jimeno, M. Luisa ; Jun, D.; Janockova, J.; Sepsova, V.; Soukup, O.; Bautista-Aguilera, Óscar M.; Refouvelet, B.; Ouari, O.; Marco-Contelles, José ; Ismaili, L.
Issue Date2016
PublisherAmerican Chemical Society
CitationJournal of Medicinal Chemistry 59: 9967-9973 (2016)
AbstractNovel multifunctional tacrines for Alzheimer's disease were obtained by Ugi-reaction between ferulic (or lipoic acid), a melatonin-like isocyanide, formaldehyde, and tacrine derivatives, according to the antioxidant additive approach in order to modulate the oxidative stress as therapeutic strategy. Compound 5c has been identified as a promising permeable agent showing excellent antioxidant properties, strong cholinesterase inhibitory activity, less hepatotoxicity than tacrine, and the best neuroprotective capacity, being able to significantly activate the Nrf2 transcriptional pathway.
Publisher version (URL)http://dx.doi.org/10.1021/acs.jmedchem.6b01178
URIhttp://hdl.handle.net/10261/152544
DOI10.1021/acs.jmedchem.6b01178
Identifiersdoi: 10.1021/acs.jmedchem.6b01178
issn: 0022-2623
e-issn: 1520-4804
Appears in Collections:(CENQUIOR) Artículos
(IQOG) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.